Clin Pediatr Hematol Oncol.  2018 Apr;25(1):17-22. 10.15264/cpho.2018.25.1.17.

Progress of Hemophilia A Therapeutics in Korea

• Kim DH
• Kim SK

• KMID: 2435419
• DOI: http://doi.org/10.15264/cpho.2018.25.1.17

Abstract

Over the past several decades, hemophilia treatment in Korea has progressed dramatically. It has become possible to prevent hemophilia complications by maintenance treatment as well as on-demand treatment with the help of the National Health Insurance program. Treatment and prevention of hemorrhage, prevention of joint complications, treatment and prevention of infectious complications have greatly improved the quality of life and life expectancy of hemophilia patients. However, the development of inhibitor is the most serious and challenging complication of clotting factor replacement therapy, although immune tolerance regimens and bypassing agents have shown some efficacy in countering this complication. The development of novel methods of therapy, including the use of extended half-life factors and gene therapy, will further improve the outcome of hemophilia patients. Administering the right drug to the right patients with the right dose at the right time will be necessary for treating the patient. Achievement of optimal therapeutic goals will require continued cooperation between patients and medical staff.

Keyword

Factor VIII; Hemophilia A; Recombinant factor VIII; Inhibitor

MeSH Terms

Factor VIII
Genetic Therapy
Half-Life
Hemophilia A*
Hemorrhage
Humans
Immune Tolerance
Joints
Korea*
Life Expectancy
Medical Staff
National Health Programs
Quality of Life
Factor VIII